文献速递肿瘤 PET/CT放射性药物与辐射防护

FDG PET/CT显像在毛霉病中的应用:早期检测与疾病监测的新方法

FDG PET/CT Imaging in Mucormycosis: A Novel Approach for Early Detection and Disease Monitoring.
PubMed 文献 · Clin Nucl Med · 2025-08-20

前瞻性观察研究纳入47例活检确诊鼻脑毛霉病成人,比较FDG PET/CT与MRI/CT并对照微生物或组织病理结果。PET/CT在35例检出代谢活跃病灶,6例(12.8%)MRI/CT显示不清,术前SUVmax 8.12高于术后6.12。结论认为PET/CT可界定病变范围、指导治疗决策并确认治疗反应。

要点

  • 47例鼻脑毛霉病中PET/CT检出35例代谢活跃病灶,6例(12.8%)MRI/CT显示不清。
  • 术前SUVmax 8.12高于术后6.12,反映术后疾病负荷降低。
  • PET/CT在32例识别残留或复发病灶,影响后续手术与药物治疗。

核心结论

  • FDG PET/CT可界定鼻脑毛霉病病变范围、指导治疗决策并确认治疗反应。
  • 将PET/CT纳入常规临床管理可能通过及时、有针对性的干预改善结局。

研究设计与样本

  • 前瞻性观察研究,纳入2022年7月至2024年9月间47例活检确诊鼻脑毛霉病成人。
  • 所有患者接受FDG PET/CT,结果与MRI/CT比较并对照微生物学或组织病理学结果。
  • PET/CT用于评估病变范围、识别残留或复发疾病并监测治疗反应。

主要发现

  • 47例患者中男43例、女4例,平均年龄49.4±12.2岁;3例术前、44例术后显像。
  • PET/CT在35例检出代谢活跃疾病,其中6例(12.8%)病灶在MRI/CT上显示不清。
  • 术前SUVmax 8.12高于术后6.12,反映术后疾病负荷降低。
  • PET/CT确认12例疾病消退且随访无复发。
  • PET/CT在32例识别残留或复发疾病,影响进一步手术与药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the role of FDG PET/CT in diagnosing and monitoring rhinocerebral mucormycosis (RCM) and its added value over conventional imaging. PATIENTS AND METHODS: We conducted a prospective observational study of 47 adults with biopsy-confirmed rhinocerebral mucormycosis between July 2022 and September 2024. All patients underwent FDG PET/CT, and findings were compared with MRI/CT and correlated with microbiological or histopathologic results. PET/CT was used to assess disease extent, identify residual or recurrent disease, and monitor treatment response. RESULTS: Of the 47 patients (43 men, 4 women; mean age 49.4 ± 12.2 y), 3 were imaged preoperatively and 44 postoperatively. PET/CT detected metabolically active disease in 35 patients, including 6 (12.8%) with lesions not well visualized on MRI/CT. Preoperative SUVmax was higher than postoperative (8.12 vs 6.12), reflecting disease burden reduction after surgery. PET/CT confirmed disease resolution in 12 patients who remained recurrence-free on follow-up. In 32 patients, PET/CT identified residual or recurrent disease, influencing further surgical and medical management. Representative images demonstrate PET/CT detection of active lesions missed on MRI/CT. CONCLUSIONS: FDG PET/CT delineates disease extent, guides therapeutic decisions, and confirms treatment response. Incorporating PET/CT into routine clinical management may improve outcomes by enabling timely, targeted interventions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Phulia A, Khan D, Kumar J, et al. FDG PET/CT Imaging in Mucormycosis: A Novel Approach for Early Detection and Disease Monitoring. Clin Nucl Med. 2025. PMID: 40831013. doi:10.1097/RLU.0000000000006104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。